News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Andrea Necchi: Results from the ECHO-307/KEYNOTE-672 study
Andrea Necchi/youtube.com
Jul 26, 2024, 19:39

Andrea Necchi: Results from the ECHO-307/KEYNOTE-672 study

Andrea Necchi, Associate Professor at Vita-Salute San Raffaele University, shared on X:

“IDO1 inhibition was ineffective in urothelial carcinoma.

Pembrolizumab and epacadostat/placebo for cis-ineligible urothelial carcinoma:

ECHO-307/KEYNOTE-672 study, BMC Cancer, also negatively tested in neoadjuvant setting.”

Source: Andrea Necchi/X

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

Authors: Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar and Ronald de Wit.

Andrea Necchi

Andrea Necchi Arjun V. Balar Avivit Peer BMC Cancer Boris Y. Alekseev Calvin Jia cancer Dmytro Trukhin ECHO-307/KEYNOTE-672 study epacadostat Francis X. Parnis Howard Gurney Jason Clark Maria De Santis Michiel S. Van der Heijden Mihaela Munteanu OncoDaily Oncology pembrolizumab Petros Grivas Raya Leibowitz Ritesh Kataria Ronald de Wit urothelial carcinoma Vita-Salute San Raffaele University
Special Coverage
Dialogues
Jan 19, 2025, 08:24
Vicki Durston: A steady increase in early-onset breast cancer among young women is drawing global attention
Blog
Jan 19, 2025, 08:21
Michael Sapienza: Amgen’s targeted therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer
Blog
Jan 19, 2025, 08:12
Daneen Sekoni: I'll be participating in the 2025 Cervical Cancer Survivor Summit
Blog
Jan 19, 2025, 08:12
SWOG Cancer Research Network study S2207 is enrolling patients with relapsed, refractory large B-cell lymphoma
Blog
Jan 19, 2025, 08:03
Targetable mutations and tumor microenvironment in urachal cancer
Career
Jan 19, 2025, 07:59
OncoInfluencers to Follow on Social Media: Kara Magsanoc-Alikpala
Science
Jan 19, 2025, 07:56
Piet Ost: Does SBRT for oligorecurrent prostate cancer improve OS as compared to SOC?
Science
Jan 19, 2025, 07:52
Paolo Tarantino: What’s distinct about Breast cancers with ERBB2?
Science
Jan 19, 2025, 07:45
Cristiane Bergerot: Mindfulness via smartphone
Science
Jan 19, 2025, 07:42
Xiuning Le: The number of newly diagnosed female lung cancer cases has surpassed that of males
Insight
Jan 19, 2025, 07:37
Stephanie Graff: Excited to have another therapeutic option to treat advanced HR+ breast cancer
Dialogues
Jan 19, 2025, 07:33
The Experience of Colorectal Cancer Screening in Kazakhstan